$MTNB
Matinas BioPharma Holdings, Inc. Stock $mtnb

$mtnb Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223027340 Filed on August 09, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q4
Revenue			$1.063M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.839M	$2.600M	$2.676M
YoY Change	0.74%	-9.14%	8.16%
% of Gross Profit
Research & Development	$3.295M	$3.559M	$3.867M
YoY Change	-11.11%	-13.75%	-8.8%
% of Gross Profit
Depreciation & Amortization	$100.0K	$98.00K	$96.73K
YoY Change	7.98%	7.39%	35.46%
% of Gross Profit
Operating Expenses	$3.295M	$3.559M	$6.543M
YoY Change	-11.11%	-13.75%	-2.55%
Operating Profit	-$6.134M	-$6.159M
YoY Change	12.29%	3.94%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$79.00K	$99.00K	$88.25K
YoY Change	7895.95%	3354.29%	505.7%
Pretax Income	-$6.055M	-$6.060M	-$3.635M
YoY Change	10.87%	2.32%	-45.75%
Income Tax
% Of Pretax Income
Net Earnings	-$6.055M	-$6.060M	-$3.635M
YoY Change	10.87%	2.32%	-45.75%
Net Earnings / Revenue			-341.91%
Basic Earnings Per Share	-$0.03	-$0.03
Diluted Earnings Per Share	-$0.03	-$0.03	-$0.02
COMMON SHARES
Basic Shares Outstanding	217.3M shares	217.3M shares	216.9M shares
Diluted Shares Outstanding	217.3M shares	217.3M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.22M	$22.51M	$28.76M
YoY Change	-44.89%	-41.53%	-42.04%
Cash & Equivalents	$6.407M	$9.743M	$6.830M
Short-Term Investments	$11.81M	$12.77M	$21.93M
Other Short-Term Assets	$1.773M	$1.487M	$5.769M
YoY Change	-56.2%	-56.54%	320.64%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$19.99M	$24.00M	$34.53M
YoY Change	-46.12%	-42.75%	-32.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.021M	$2.103M	$2.091M
YoY Change	-5.74%	6.05%	35.96%
Goodwill	$1.336M	$1.336M	$1.336M
YoY Change	-0.04%	-0.04%	-0.04%
Intangibles	$3.017M	$3.017M	$3.017M
YoY Change	-0.01%	-0.01%	-0.01%
Long-Term Investments
YoY Change
Other Assets	$200.0K	$200.0K	$200.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$9.802M	$10.03M	$10.29M
YoY Change	-6.17%	-4.45%	-0.44%
TOTAL ASSETS
Total Short-Term Assets	$19.99M	$24.00M	$34.53M
Total Long-Term Assets	$9.802M	$10.03M	$10.29M
Total Assets	$29.79M	$34.03M	$44.82M
YoY Change	-37.34%	-35.09%	-26.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$835.0K	$604.0K	$618.0K
YoY Change	27.15%	21.49%	-34.13%
Accrued Expenses	$1.757M	$1.372M	$3.099M
YoY Change	-52.47%	-68.05%	8.7%
Deferred Revenue			$721.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.000K	$5.000K	$7.000K
YoY Change	-36.39%	-56.56%	-66.73%
Total Short-Term Liabilities	$3.229M	$2.589M	$4.286M
YoY Change	-34.12%	-51.9%	-1.44%
LONG-TERM LIABILITIES
Long-Term Debt	$19.00K	$20.00K	$22.00K
YoY Change			739.69%
Other Long-Term Liabilities	$3.052M	$3.221M	$3.533M
YoY Change	-17.15%	-16.2%	-14.67%
Total Long-Term Liabilities	$3.412M	$3.582M	$3.896M
YoY Change	-15.23%	-14.4%	-13.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.229M	$2.589M	$4.286M
Total Long-Term Liabilities	$3.412M	$3.582M	$3.896M
Total Liabilities	$6.641M	$6.171M	$8.182M
YoY Change	-25.61%	-35.5%	-7.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$170.3M	-$164.2M	-$152.6M
YoY Change	14.27%	14.43%	15.95%
Common Stock	$22.00K	$22.00K	$22.00K
YoY Change	1.45%	1.45%	1.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.15M	$27.85M	$36.64M
YoY Change
Total Liabilities & Shareholders Equity	$29.79M	$34.03M	$44.82M
YoY Change	-37.34%	-35.09%	-26.92%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q4
OPERATING ACTIVITIES
Net Income	-$6.055M	-$6.060M	-$3.635M
YoY Change	10.87%	2.32%	-45.75%
Depreciation, Depletion And Amortization	$100.0K	$98.00K	$96.73K
YoY Change	7.98%	7.39%	35.46%
Cash From Operating Activities	-$4.419M	-$2.193M	-$4.299M
YoY Change	-11.06%	-57.27%	8.63%
INVESTING ACTIVITIES
Capital Expenditures	$16.00K	$202.0K	$41.60K
YoY Change	-106.39%	-464.03%	-214.95%
Acquisitions
YoY Change
Other Investing Activities	$1.100M	$6.400M	-$410.00
YoY Change	-81.67%	-271.3%	-100.44%
Cash From Investing Activities	$1.084M	$6.198M	-$42.01K
YoY Change	-81.15%	-263.46%	-174.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.000K	-1.000K	-4.640K
YoY Change	-72.6%	-82.24%	-157.35%
NET CHANGE
Cash From Operating Activities	-4.419M	-2.193M	-4.299M
Cash From Investing Activities	1.084M	6.198M	-42.01K
Cash From Financing Activities	-1.000K	-1.000K	-4.640K
Net Change In Cash	-3.336M	4.004M	-4.346M
YoY Change	-529.18%	-144.84%	11.64%
FREE CASH FLOW
Cash From Operating Activities	-$4.419M	-$2.193M	-$4.299M
Capital Expenditures	$16.00K	$202.0K	$41.60K
Free Cash Flow	-$4.435M	-$2.395M	-$4.341M
YoY Change	-6.01%	-52.82%	10.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001582554
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2022Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff		usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax		usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax		usd
CY2023Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2023Q2	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities		usd
CY2023Q2	MTNB	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour		usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38022
	dei	Entity Registrant Name EntityRegistrantName	MATINAS BIOPHARMA HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3011414
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1545 Route 206 South
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 302
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bedminster
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07921
	dei	City Area Code CityAreaCode	908
	dei	Local Phone Number LocalPhoneNumber	484-8805
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	MTNB
	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	217264526	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9743000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6830000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	12770000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	21933000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	50000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	50000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1437000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5719000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	24000000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	34532000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2103000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2091000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3345000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3613000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	24000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	30000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3017000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3017000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	1336000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1336000	usd
CY2023Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	200000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	200000	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	10025000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	10287000	usd
CY2023Q2	us-gaap	Assets Assets	34025000	usd
CY2022Q4	us-gaap	Assets Assets	44819000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	604000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	618000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1372000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3099000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	608000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	562000	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	5000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2589000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4286000	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	341000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	341000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3221000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3533000	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	22000	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3582000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3896000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	6171000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8182000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	217264526	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	217264526	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	217264526	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	217264526	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	22000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	22000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	192550000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	190070000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-164204000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152631000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-514000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-824000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	27854000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	36637000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34025000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44819000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1063000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1096000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1063000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3559000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4127000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7530000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9105000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2600000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2861000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5311000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5606000	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	6159000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	6988000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	12841000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	14711000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6159000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5925000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11745000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13648000	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	1734000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	99000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	172000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6060000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5923000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11573000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11901000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	217264526	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	217264526	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	216864526	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	216864526	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	217264526	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	217264526	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	216755261	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	216755261	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	217264526	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	217264526	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	216864526	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	216864526	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	217264526	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	217264526	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	216755261	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	216755261	shares
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	81000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-125000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	310000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-609000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	81000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-125000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	310000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-609000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5979000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6048000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11263000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12510000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	36637000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2480000	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	310000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11573000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	27854000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	32625000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1208000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	81000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-6060000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	27854000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	52494000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2475000	usd
	MTNB	Stock Issued During Period Value Common Stock In Exchange For Options StockIssuedDuringPeriodValueCommonStockInExchangeForOptions	99000	usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	291000	usd
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-609000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11901000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	42849000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	47682000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	47682000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1215000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-125000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5923000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	42849000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	42849000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11573000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11901000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	190000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	155000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2480000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2475000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	268000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	275000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	12000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	73000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	110000	usd
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	291000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-266000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-256000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4282000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2050000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-13000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-441000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1726000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1443000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6280000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9887000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9481000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	9400000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	9250000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	202000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	600000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9198000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-831000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	99000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	12000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	87000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2913000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10631000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7080000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21280000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9993000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10649000	usd
	MTNB	Noncash Financing Unrealized Loss On Marketable Securities NoncashFinancingUnrealizedLossOnMarketableSecurities	310000	usd
	MTNB	Noncash Financing Unrealized Loss On Marketable Securities NoncashFinancingUnrealizedLossOnMarketableSecurities	-609000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80F_eus-gaap--NatureOfOperations_zkUhTWEtQJc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Note 1 – <span id="xdx_82A_z5KiqCrMEbC9">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Matinas BioPharma Nanotechnologies, Inc. (“Nanotechnologies,” formerly known as Aquarius Biotechnologies, Inc.), its operating subsidiaries (“Nanotechnologies”, and together with “Holdings” and “BioPharma”, “the Company”). The Company is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-164204000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11573000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9743000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	12770000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	250000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	250000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	250000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9743000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6830000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10399000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21030000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	250000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	250000	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	250000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	250000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9993000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7080000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10649000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21280000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	81000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	310000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-125000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-609000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	514000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	824000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	13284000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	514000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	12770000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	5936000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	6834000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	12770000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	22757000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	824000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	21933000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	13240000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	8693000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	21933000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	12770000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	21933000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	21933000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3662000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3460000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3662000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3460000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1559000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1369000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2103000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2091000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	97000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	190000	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	86000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	155000	usd
CY2023Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1027000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1705000	usd
CY2023Q2	MTNB	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	257000	usd
CY2022Q4	MTNB	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	455000	usd
CY2023Q2	MTNB	Accrued General And Administrative Expenses Current AccruedGeneralAndAdministrativeExpensesCurrent	88000	usd
CY2022Q4	MTNB	Accrued General And Administrative Expenses Current AccruedGeneralAndAdministrativeExpensesCurrent	130000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	721000	usd
CY2022Q4	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	88000	usd
CY2023Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1372000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3099000	usd
	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	Some leases include purchase, termination or extension options for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised.
CY2023Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P12M
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	226000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	226000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	452000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	452000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	135000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	268000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	139000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	275000	usd
CY2023Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000	usd
CY2022Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5000	usd
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	6000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	12000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	467000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	4000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	956000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	7000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	998000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	7000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1040000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	7000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	944000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	7000	usd
CY2023Q2	MTNB	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	411000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4816000	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	32000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	987000	usd
CY2023Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	7000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3829000	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	25000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M18D
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y4M24D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.092	pure
CY2023Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.116	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	916000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	10000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	956000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	7000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	998000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	7000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1040000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	7000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	944000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	7000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	411000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5265000	usd
CY2022Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	38000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1170000	usd
CY2022Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	9000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4095000	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	29000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.092	pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.111	pure
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1734000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	988000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	400000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	350000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	238000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	238000	shares
CY2023Q1	MTNB	Increased Shares Of Common Stock Outstanding IncreasedSharesOfCommonStockOutstanding	8691000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	4	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	34544000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28717000	shares
CY2022Q4	MTNB	Net Unrealized Gains Losses On Availableforsale Securities NetUnrealizedGainsLossesOnAvailableforsaleSecurities	-824000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-824000	usd
	MTNB	Net Unrealized Gains Losses On Availableforsale Securities Net Unrealized Loss On Securities Availableforsale NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesNetUnrealizedLossOnSecuritiesAvailableforsale	310000	usd
	MTNB	Accumulated Other Comprehensive Lossgain Net Unrealized Loss On Securities Availableforsale AccumulatedOtherComprehensiveLossgainNetUnrealizedLossOnSecuritiesAvailableforsale	310000	usd
CY2023Q2	MTNB	Net Unrealized Gains Losses On Availableforsale Securities NetUnrealizedGainsLossesOnAvailableforsaleSecurities	-514000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-514000	usd
CY2021Q4	MTNB	Net Unrealized Gains Losses On Availableforsale Securities NetUnrealizedGainsLossesOnAvailableforsaleSecurities	-145000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-145000	usd
	MTNB	Net Unrealized Gains Losses On Availableforsale Securities Net Unrealized Loss On Securities Availableforsale NetUnrealizedGainsLossesOnAvailableforsaleSecuritiesNetUnrealizedLossOnSecuritiesAvailableforsale	-609000	usd
	MTNB	Accumulated Other Comprehensive Lossgain Net Unrealized Loss On Securities Availableforsale AccumulatedOtherComprehensiveLossgainNetUnrealizedLossOnSecuritiesAvailableforsale	-609000	usd
CY2022Q2	MTNB	Net Unrealized Gains Losses On Availableforsale Securities NetUnrealizedGainsLossesOnAvailableforsaleSecurities	-754000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-754000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1208000	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1215000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2480000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2475000	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7437	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	34739000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	65000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	221000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	39000	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	34544000	shares

Files In Submission

Name	View Source	Status
0001493152-23-027340-index-headers.html	Edgar Link	pending
0001493152-23-027340-index.html	Edgar Link	pending
0001493152-23-027340.txt	Edgar Link	pending
0001493152-23-027340-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mtnb-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
mtnb-20230630_cal.xml	Edgar Link	unprocessable
mtnb-20230630_def.xml	Edgar Link	unprocessable
mtnb-20230630_lab.xml	Edgar Link	unprocessable
mtnb-20230630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MTNB
Matinas BioPharma Holdings, Inc. Stock $mtnb

2023 Q3 Form 10-Q Financial Statement

#000149315223027340 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTNB Matinas BioPharma Holdings, Inc. Stock $mtnb

2023 Q3 Form 10-Q Financial Statement

#000149315223027340 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTNB
Matinas BioPharma Holdings, Inc. Stock $mtnb